All data are based on the daily closing price as of November 12, 2026
a

Alar Pharmaceuticals

6785.TWO
2.46 USD
0.02
+0.82%

Overview

Last close
2.46 usd
Market cap
164.03M usd
52 week high
9.84 usd
52 week low
2.25 usd
Target price
8.8 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
1781.3334
Price/Book Value
2.2511
Enterprise Value
93.10M usd
EV/Revenue
1022.546
EV/EBITDA
413.1064

Key financials

Revenue TTM
91047.04 usd
Gross Profit TTM
78664.64 usd
EBITDA TTM
-5.11M usd
Earnings per Share
-0.03 usd
Dividend
N/A usd
Total assets
77.04M usd
Net debt
N/A usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
  • Symbol
    6785.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Yung-Shun Wen Ph.D.
  • Headquarter
    Taichung
  • Web site
    https://alarpharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top